Egf816

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Egf816 is an investigational medication currently being studied by Novartis Pharmaceuticals. It is being evaluated in clinical trials, including one for colorectal cancer (CRC). The trial (NCT02900664) is a Phase 1 study designed to assess the safety, tolerability, and potential anti-tumor activity of Egf816 when given in combination with other investigational drugs (PDR001, CJM112) or standard treatments (like canakinumab or trametinib) in patients with various cancers, including CRC. This early-phase trial helps researchers understand the best way to use Egf816 and determine if it has activity against certain cancers. It is important to note that Egf816 is not yet approved for treating CRC or any other condition.

Mechanism of Action

The specific way Egf816 works (its mechanism of action) is being investigated in clinical trials. It is being studied in combination with other agents, suggesting it may target pathways involved in tumor growth or the immune response to cancer. The trial aims to characterize its pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body).

Side Effects

As Egf816 is an investigational drug in early-phase clinical trials Detailed information about its side effects is still being gathered. The Phase 1 trial (NCT02900664) focuses on assessing the safety and tolerability of Egf816 Both as a single agent and in combination with other drugs. Specific side effects observed in the trial are not detailed in the provided information But researchers are carefully monitoring participants for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02900664 Phase 1
Archived
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
United States, Belgium, Canada, France, Israel, Italy, Singapore, Spain, Taiwan

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.